diff --git a/domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md b/domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md index 6aa2998fe..8be708c45 100644 --- a/domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md +++ b/domains/health/glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials.md @@ -31,3 +31,10 @@ Exenatide Phase 3 showed no DaT-SPECT signal change versus placebo, meaning the **Source:** Holscher 2024 review + exenatide Phase 3 CSF data (Lancet Feb 2025) Exenatide Phase 3 CSF analysis revealed that BBB crossing (a pharmacokinetic surrogate) doesn't predict substantia nigra penetrance (the therapeutic target). Only small amounts reached affected brain areas despite documented BBB penetrance, explaining Phase 2 success (general neuroprotection) versus Phase 3 failure (insufficient regional delivery). + + +## Supporting Evidence + +**Source:** PMC12374370 meta-analysis 2025 + +Updated meta-analysis (5 RCTs, n=708) shows MDS-UPDRS Part III improvement of only -2.06 points (95% CI -4.09 to -0.03)—statistically significant but clinically marginal. No improvement in MDS-UPDRS Parts I, II, IV, no levodopa dose reduction, no PDQ-39 quality of life improvement, and no Non-Motor Symptoms Scale improvement. This confirms that motor biomarker changes do not translate to functional benefit in Parkinson's GLP-1 trials. diff --git a/domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md b/domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md index 14ac2c140..7fa0342bb 100644 --- a/domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md +++ b/domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md @@ -38,3 +38,10 @@ GLP-1 receptor expression in ventral tegmental area (VTA) and nucleus accumbens **Source:** LIXIPARK NEJM April 2024 LIXIPARK demonstrated motor symptom stabilization in early Parkinson's disease (dopaminergic neurodegeneration) at 12 months, challenging the blanket claim that GLP-1s fail in neurodegeneration. However, this is Phase 2 in early disease only, and the lack of Phase 3 funding post-publication suggests the field remains skeptical. The divergence from exenatide Phase 3 failure indicates disease stage and drug-specific penetrance may be boundary conditions. + + +## Extending Evidence + +**Source:** PMC12374370 + Lancet exenatide Phase 3 Feb 2025 + +Exenatide Phase 3 failure (Lancet Feb 2025) with CSF analysis showing BBB crossing but insufficient substantia nigra penetrance provides mechanistic explanation: GLP-1 agonists succeed in reward circuits (VTA, nucleus accumbens) but fail in neurodegeneration (substantia nigra) due to regional CNS access differences, not circuit-specific receptor distribution. Lixisenatide Phase 2 success suggests within-class variation in regional penetrance. diff --git a/entities/health/most-able-trial.md b/entities/health/most-able-trial.md new file mode 100644 index 000000000..3a73ef516 --- /dev/null +++ b/entities/health/most-able-trial.md @@ -0,0 +1,39 @@ +--- +type: entity +entity_type: research_program +name: MOST-ABLE Trial +full_name: Oral Semaglutide for Parkinson's Disease Motor Symptoms Trial +domain: health +status: active +--- + +# MOST-ABLE Trial + +**Type:** Phase 2/3 randomized controlled trial +**Intervention:** Oral semaglutide 7mg and 14mg daily +**Population:** n=99 patients with Parkinson's disease +**Location:** Japan +**Primary Endpoint:** Motor symptom improvement (MDS-UPDRS Part III) + +## Overview + +MOST-ABLE is the first randomized controlled trial testing semaglutide specifically for Parkinson's disease motor symptoms. Unlike prior GLP-1 Parkinson's trials (exenatide, liraglutide, lixisenatide), this study uses oral semaglutide, which has a distinct CNS access mechanism via tanycytes targeting hypothalamus and brainstem regions. + +## Significance + +The trial addresses a critical evidence gap: all prior GLP-1 Parkinson's RCTs used older GLP-1 agonists with different CNS penetrance profiles. Exenatide's Phase 3 failure (Lancet Feb 2025) revealed that blood-brain barrier crossing does not guarantee substantia nigra penetrance. Semaglutide's tanycyte-mediated CNS access may provide superior regional distribution, but this remains empirically unproven. + +## Timeline + +- **2024** — Protocol published, enrollment completed +- **Nov-Dec 2025** — Data collection completed +- **2026** — Results expected (as of May 2026, publication pending) + +## Context + +Meta-analysis of 5 prior GLP-1 Parkinson's RCTs (n=708) shows narrow motor benefit (MDS-UPDRS Part III -2.06, 95% CI -4.09 to -0.03) but no functional quality of life improvement. MOST-ABLE results will determine whether semaglutide's distinct CNS access mechanism translates to superior clinical efficacy. + +## Sources + +- PMC12374370 meta-analysis (Jan 2025) +- Session 40 GLP-1 Parkinson's divergence analysis (May 2026) \ No newline at end of file diff --git a/inbox/queue/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md b/inbox/archive/health/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md similarity index 97% rename from inbox/queue/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md rename to inbox/archive/health/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md index b31ab1591..2f5ab50f3 100644 --- a/inbox/queue/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md +++ b/inbox/archive/health/2026-05-09-pmc12374370-glp1-parkinson-updated-meta-analysis-2025.md @@ -7,10 +7,13 @@ date: 2025-01-01 domain: health secondary_domains: [] format: research -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-09 priority: medium tags: [GLP-1, Parkinson's-disease, meta-analysis, semaglutide, exenatide, lixisenatide, neuroprotection, motor-symptoms] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content